The Enterprise Value as of December 2024 (TTM) for Genelux Corporation (GNLX) is 78.48M

According to Genelux Corporation’s latest financial reports and current stock price. The company's current Enterprise Value is 78.48M. This represents a change of -50.50% compared to the average of 158.54M of the last 4 quarters.

Genelux Corporation (GNLX) Historical Enterprise Value (quarterly & annually)

How has GNLX Enterprise Value performed in the past?

The mean historical Enterprise Value of Genelux Corporation over the last ten years is 200.22M. The current 78.48M Enterprise Value has changed 3.82% with respect to the historical average. Over the past ten years (40 quarters), GNLX's Enterprise Value was at its highest in in the June 2023 quarter at 820.73M. The Enterprise Value was at its lowest in in the June 2024 quarter at 48.98M.

Genelux Corporation (GNLX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Genelux Corporation Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Genelux Corporation (GNLX) Average Enterprise Value

How has GNLX Enterprise Value performed in the past?

The current Enterprise Value of Genelux Corporation (GNLX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Genelux Corporation (GNLX) Enterprise Value vs. Peers

How is GNLX’s Enterprise Value compared to its peers?

Genelux Corporation’s Enterprise Value is greater than Comera Life Sciences Holdings, Inc. (-1590126.00), greater than Dyadic International, Inc. (50.93M), greater than Cingulate Inc. (5.81M), less than Monopar Therapeutics Inc. (110.36M), less than Terns Pharmaceuticals, Inc. (223.81M), less than Day One Biopharmaceuticals, Inc. (857.57M), less than Acumen Pharmaceuticals, Inc. (104.35M), less than Amylyx Pharmaceuticals, Inc. (204.92M), less than MoonLake Immunotherapeutics (2.95B), less than Monte Rosa Therapeutics, Inc. (351.25M), less than NewAmsterdam Pharma Company N.V. (2.35B), less than Inventiva S.A. (222.87M), less than Cullinan Oncology, Inc. (614.81M), less than Compass Therapeutics, Inc. (176.46M), less than Larimar Therapeutics, Inc. (211.48M), greater than Immuneering Corporation (28.90M), less than Centessa Pharmaceuticals plc (1.91B), less than Celcuity Inc. (549.83M), greater than Ikena Oncology, Inc. (37.04M),

Build a custom stock screener for Genelux Corporation (GNLX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Genelux Corporation using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Genelux Corporation (GNLX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Genelux Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.